Document is current

Article History

Received: 17 October 2024

Accepted: 22 February 2025

First Online: 11 March 2025

Declarations

:

: The current study is part of a wider clinical evaluation of the first residential treatment facility for the treatment of EDs in Australia. This study was prospectively registered with the Australian New Zealand Clinical Trials Registry (ANZCTR12621001651875p). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. All procedures involving human subjects/patients were approved from the Western Sydney University Human Research Ethics Committee (Approval H14742). All participants provided written and verbal informed consent.

: The authors confirm that all participants provided written and verbal informed consent, including consent for the publication of deidentified data in academic journals. Their consent to publish was obtained in writing as part of the informed consent process. Additionally, the final manuscript was sent to participants for member checking, prior to submission, and any feedback received was reflexively incorporated into the manuscript to ensure optimal accuracy in representing the participants’ experiences.

: Rebekah Rankin is a doctoral student currently supported by the Western Sydney University Butterfly Foundation Postgraduate Research Scholarship, which is jointly funded by Western Sydney University and the Butterfly Foundation. She is also the recipient of a top-up scholarship from the Digital Health Cooperative Research Centre. Phillipa Hay, Janet Conti and Lucie Ramjan received funding from the Butterfly Foundation for the clinical evaluation of the Wandi Nerida program. Phillipa Hay receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and HETI (New South Wales and the former NSW Institute of Psychiatry). She has received royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, Blackwell Scientific Publications, Biomed Central and PlosMedicine and research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia (2019-ongoing), was a Member of the ICD-11 Working Group for Eating Disorders and was Chair of the Clinical Practice Guidelines Project Working Group (eating disorders) of RANZCP (2012–2015). She is a co-editor-in-chief of the Journal of Eating Disorders. She has been a consultant to Takeda Pharmaceuticals and is a consultant to Tryptamine Therapeutics. All views in this paper are her own.